Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise.
Dr Fandi brings more than 25 years of experience of oncology clinical development programs in the pharmaceutical and biotechnology industry. He joins from Oxford Biotherapeutics, where he held the role of Chief Medical Officer and was a member of the Executive Committee, playing a pivotal role in leading all clinical and regulatory aspects of the oncology pipeline and multi-disciplinary teams across two sites. Prior to this, Rahim held senior clinical research and development positions at Celgene, Novartis, Bristol Myers Squibb and AstraZeneca. Dr Fandi started his career at Sanofi Winthrop.
Karine Rossignol, Chief Executive Officer of Smart Immune, said: “Rahim’s extensive experience in clinical development to explore new immuno-oncology technologies will be an invaluable asset to Smart Immune. In this role, Rahim will be instrumental in advancing our clinical-stage ProTcell derived product, beyond post transplantation hematology. The applications to improve patients’ prognosis in both hematological and solid tumors indications are very exciting.”
Dr. Rahim Fandi M.D, PhD, Chief Medical Officer of Smart Immune, said: “I am excited to be joining the talented Smart Immune team at such a critical juncture in the Company’s development. I look forward to working with the leadership team, board of directors, and the KOLs of the clinical advisory board to help patients with life-threatening diseases to live longer and better. The Phase I/II ReSET-02 trial is recruiting at a very encouraging speed with the goal to define the optimal dose in adults followed by the expansion of the clinical program to other hematological malignancies and solid tumors.”